Siemiątkowska Anna, Bryl Maciej, Kosicka-Noworzyń Katarzyna, Tvrdoň Jakub, Gołda-Gocka Iwona, Barinow-Wojewódzki Aleksander, Główka Franciszek K
Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego Street, 60-781 Poznań, Poland.
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Cancers (Basel). 2021 Jul 23;13(15):3702. doi: 10.3390/cancers13153702.
Prognosis of advanced non-small cell lung carcinoma (NSCLC) is poor. Even though it can improve with anti-PD-1/PD-L1 agents, most patients do not respond to treatment. We hypothesized that the serum soluble form of the unit α of the interleukin-2 receptor (sCD25) could be used as a biomarker of successful immunotherapy in NSCLC. We recruited patients dosed with atezolizumab ( = 42) or pembrolizumab ( = 20) and collected samples at baseline and during the treatment. Levels of sCD25 were quantified with the ELISA kits. Patients with a high sCD25 at baseline (sCD25.0 ≥ 5.99 ng/mL) or/and at the end of the fourth treatment cycle (sCD25.4 ≥ 7.73 ng/mL) progressed faster and lived shorter without the disease progression and serious toxicity. None of the patients with high sCD25 at both time points continued therapy longer than 9.3 months, while almost 40% of patients with low sCD25 were treated for ≥12.3 months. There was a 6.3-times higher incidence of treatment failure (HR = 6.33, 95% CI: 2.10-19.06, = 0.001) and a 6.5-times higher incidence of progression (HR = 6.50, 95% CI: 2.04-20.73, = 0.002) in patients with high compared with low sCD25.0 and sCD25.4. Serum levels of sCD25 may serve as a non-invasive biomarker of long-term benefits from the anti-PD-1/PD-L1s in NSCLC.
晚期非小细胞肺癌（NSCLC）的预后较差。尽管抗PD-1/PD-L1药物可改善其预后，但大多数患者对治疗无反应。我们推测，白细胞介素-2受体α单位的血清可溶性形式（sCD25）可作为NSCLC免疫治疗成功的生物标志物。我们招募了接受阿替利珠单抗（n = 42）或帕博利珠单抗（n = 20）治疗的患者，并在基线和治疗期间采集样本。使用ELISA试剂盒对sCD25水平进行定量。基线时sCD25水平高（sCD25.0≥5.99 ng/mL）或/和在第四个治疗周期结束时（sCD25.4≥7.73 ng/mL）的患者，在无疾病进展和严重毒性的情况下，疾病进展更快，生存期更短。两个时间点sCD25水平均高的患者，无一人持续治疗超过9.3个月，而sCD25水平低的患者中近40%接受了≥12.3个月的治疗。与sCD25.0和sCD25.4水平低的患者相比，sCD25水平高的患者治疗失败的发生率高6.3倍（HR = 6.33，95%CI：2.10 - 19.06，P = 0.001），疾病进展的发生率高6.5倍（HR = 6.50，95%CI：2.04 - 20.73，P = 0.002）。sCD25的血清水平可能作为NSCLC患者从抗PD-1/PD-L1治疗中获得长期益处的非侵入性生物标志物。
